Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides

Mycosis Fungoides Clinical Trial

— Resimmune®  

Official title:

Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (Resimmune®) in Subjects With Mycosis Fungoides: A Phase II Multi-center Randomized Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02943642
• Other study ID #: FDA IND 100712 Phase II
• Status: Not yet recruiting
• Phase: Phase 2
• First received: October 18, 2016
• Last updated: October 21, 2016
• Start date: January 2017
• Est. completion date: May 2020

Study information

• Verified date: October 2016
• Source: Angimmune LLC
• Contact: Paul H Neville
• Phone: 5083978150
• Email: pauln[@]angimmune.com
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study evaluates the effectiveness — as judged by complete response — of a single four-day treatment with the fusion protein A-dmDT390-bisFv(UCHT1) compared to oral Zolinza (Vorinostat), in a randomized 2-arm trial after a maximum of 12 months of treatment. Patient eligibility is stage IB/IIB mycosis fungoides with mSWAT < 50 who have never had lymphoid disease or a prior bone marrow / HSCT transplant.

Description:

Primary Objective: This study objective is to document the incidence of complete responses compared to oral vorinostat, in a randomized 2-arm trial after a maximum of 12 months of treatment for subjects with stage IB/IIB mycosis fungoides with mSWAT < 50 who have never had lymphoid disease or a prior bone marrow / HSCT transplant.

Secondary Objective: To further explore the toxicity profile of A-dmDT390-bisFv(UCHT1) fusion protein for subjects with mycosis fungoides who have been selected to be free from preexisting cardiac disease and never treated with Campath.

Number of Subjects: Lead-in Dosing: 12 / Randomized: 162

Patients will receive full supportive care during the course of the study. Participation in the study will require IV infusions of the research agent 2 times a day for four days (protocol FDA outpatient approved), as well as frequent outpatient blood draws for the first 30 days. Patients with partial or complete remissions at their 1 month follow up visit will have another follow-up visit on day 60, then every three months for 1 year, followed by annual visits to assess duration of the response.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 162
• Est. completion date: May 2020
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must have signed the current IRB approved informed consent prior to registration (see Informed Consent).

• Mycosis fungoides, confirmed by biopsy or flow cytometry, without large cell transformation.

• Relapse or progression after 2 or more systemic therapies. Note: Total electron beam therapy can be counted as a systemic therapy.

• Disease stage as follows:

• Stage IB with no lymph node involvement including lymphadenopathy with mSWAT <50;

• Stage IIB with no lymph node involvement including lymphadenopathy with mSWAT <50.

• Age 18 years.

• Subjects must have a performance status of < 2 on Eastern Cooperative Oncology Group scale (see Appendix A).

• Subjects must have normal lung function evaluated by pulse oximetry with O2 saturation values between 95-100%.

• Subjects must have fully recovered from toxicity of prior chemotherapy or radiation therapy.

• Subjects must have:

• bilirubin < 1.5 mg/dL,

• transaminases < 2.5 X ULN,

• albumin > 3 gm/dL,

• creatinine < 2.0 mg/dL.

• Subjects who have had albumin < 3 gm/dL boosted by an albumin infusion must be observed to maintain albumin at > 3gm dL for 14 days without an additional infusion.

• Subjects must have a normal echocardiogram (EF > 50% normal) without any evidence of cardiac chamber hypertrophy, dilatation or hypokinesis.

• Females and males must be willing to use an approved form of birth control while on this study and for 2 weeks after completion.

• Subjects must have a pretreatment anti-DT titer of 20 µg/ml or less. Subjects with titers between 21 and 35 µg/ml will have an additional anti-DT neutralization test using subject's serum and A-dmDT390-bisFv(UCHT1). If neutralization is not found these titers will be considered acceptable.

Exclusion Criteria:

• Failure to meet any of the criteria.

• Inability to give informed consent because of psychiatric problems, or complicated medical problems.

• Allergic to diphtheria toxin a component of the study drug A-dmDT390-bisFv(UCHT1).

• Serious concurrent medical problems, uncontrolled infections, or disseminated intravascular coagulopathy (DIC), hepatic cirrhosis, or chronic kidney disease.

• CNS leukemia.

• Preexisting cardiovascular disease. The only exception being well controlled essential hypertension with a sitting blood pressure (B.P.) of <160 systolic and <90 diastolic without any evidence of structural heart disease or one episode of myocardial infarction > 8 months ago. Subjects receiving a beta-blocker for hypertension should be converted to another antihypertensive drug class 2-3 weeks before receiving the study drug to prevent a drug-drug interaction reactive tachycardia. Angiotensin inhibitors, angiotensin receptor blockers and calcium channel blockers are all acceptable. A past history of any of the following conditions is considered as exclusions to study participation:

• Congestive heart failure,

• Atrial fibrillation,

• Pulmonary hypertension,

• Anticoagulant drug therapy,

• Thromboembolic events,

• Cardiomyopathy or a myocardial infarction within the past 8 months. The PI and the Clinical Coordinator will be asked to verify that their referred subjects do not have these exclusionary histories listed in 3.2 and a copy of this verification must be sent to the Sponsor before the Sponsor will approve of enrollment. Referring physicians will not need to sign.

• Pregnant or nursing women will be excluded from study.

• History of cirrhosis of the liver based on the Child-Pugh score of Class B or C are not eligible to participate.

• Prior treatment with alemtuzumab (Campath) or similar agents or procedures that depress blood T cell counts to below 50% of the lower limit of normal.

• Prior history of bone marrow transplant or HSCT is an exclusion.

• Prior treatment with vorinostat (Prior treatment with vorinostat for lead-in dosing arm is acceptable).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Mycoses
• Mycosis Fungoides

Intervention

Biological:
• A-dmDT390-bisFv(UCHT1)
anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)

Drug:
• Vorinostat
ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

Locations

Country	Name	City	State
n/a

Sponsors (18)

Lead Sponsor

Collaborator

Angimmune LLC

City of Hope National Medical Center, Columbia University, Dana-Farber Cancer Institute, Feinberg School of Medicine, Northwestern University, H. Lee Moffitt Cancer Center and Research Institute, Ohio State University Comprehensive Cancer Center, Rush University Medical Center, Scott and White Hospital & Clinic, Stanford University, Thomas Jefferson University, University of Arkansas, University of Colorado Denver School of Medicine Barbara Davis Center, University of Texas Southwestern Medical Center, University of Washington, Vanderbilt University School of Medicine, Washington University School of Medicine, Yale University

References & Publications (1)

Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3e recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015 Jun;100(6):794-800. doi: 10.3324/haematol.2015 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Primary Toxicity profile	Determine the Primary Toxicity profile for treatment of A-dmDT390-bisFv(UCHT1). Toxicities from the previous phase I clinical trial known to be associated with A-dmDT390-bisFv(UCHT1) include: Frequent: elevated AST, ALT and CPK; hypersensitivity reactions such as rigors and chills during infusions, hypoalbuminemia.; Rare: Vascular leak syndrome.; Hypersensitivity infusion reaction.	3 months	Yes
Primary	Incidence of Complete Responses (CR)	Evaluation of Target Lesions; Complete Response (CR) in mycosis fungoides: (a) Cutaneous lesions consisting of erythematous patches and plaques and erythroderma must be absent giving an mSWAT of 0 that persists for at least 30 days, and (b) the spleen and liver should be normal sized by physical exam. Subjects in the experimental arm who have a CR at 12 months will be encouraged to enter the Part B followup that consists of a a yearly physical exam from year 2 to year to year 6 and skin assessment as long as the CR is maintained.; Partial Response (PR) in mycosis fungoides: (a) There must be a reduction of 50% in cutaneous lesions as judged by mSWAT and (b) no new evidence of disease or disease progression of skin lesions.; Progressive Disease (PD): At least a 25% increase in the mSWAT score from its nadir value.; Treatment Failure: Failure to achieve a PR or CR: Relapse/Progression: Relapse is defined at reevaluation as no longer a CR or PR.	Skin lesions will be judged for mSWAT scores for judging the duration of response at 12 months in the experimental arm and 6 months in the comparator arm.	No
Secondary	Progression Free Survival	Determine the Progression Free Survival duration, PFS	12 months	No
Secondary	Median duration of Complete Response	Determine the Median duration of CR for each arm.	12 months	No